Background: We organized and conducted a proficiency testing study (CardioOrmocheck) to evaluate the differences in analytical performance of brain natriuretic peptide (BNP) and N-terminal proBNP (NTproBNP) immunoassays. Results: The mean total variability for BNP (50.6 %CV) was significantly higher than that for NT-proBNP (8.4 %CV). In addition, the mean variability due to differences between-methods (46.4 %CV) comprised the majority of the total variability for BNP. Betweenmethod variability for BNP comprised, on average, 84% of total variability, while the within-method variability comprised an average of 20.2 %CV. On the contrary, for NT-proBNP the within-method variability (7.3 %CV) represented the majority of total variability (average 75%), while between-method variability was smaller (4.1 %CV). Imprecision around the cut-off value showed marked differences among methods, especially for BNP immunoassay methods. In addition, BNP methods were affected by large systematic differences, for example an average 2.7-fold difference between Access and ADVIA Centaur methods, while agreement between NT-proBNP methods was better (an average 1.2-fold difference between Dimension and ECLIA on the Elecsys methods).
Introduction
Cardiac natriuretic peptides, which include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and their related pro-hormones (proANP and proBNP), constitute a complex family of peptide hormones produced and secreted by the heart. ANP and BNP are greatly increased in diseases characterized by an expanded fluid volume, especially heart failure (1). The active peptides, ANP and BNP, are produced by cleavage of the COOH-terminal part of the pro-hormone (proANP and pro-BNP), while the N-terminal fragments of pro-hormone, NT-proANP and NTproBNP, are currently considered inactive (1, 2) .
Measurement of BNP and its related-peptides is considered a useful marker of myocardial function (1) (2) (3) (4) (5) (6) , and has been recently included, along with the ECG and radiogram of the thorax, in the first step of the algorithm for diagnosis of heart failure as proposed by the Task Force of the European Society of Cardiology (7, 8) . Recent meta-analyses (4, 5) have confirmed that BNP and NT-proBNP assays have a high degree of diagnostic accuracy and clinical relevance in both acute and chronic heart failure. However, several studies suggest that there are significant differences in the analytical and clinical characteristics, including differences in reference ranges, decision levels and cut-off values, among immunoassays for B-type related peptides that might allow misleading clinical interpretation (9) (10) (11) (12) .
In order to evaluate the differences in analytical performance and clinical utility of the most commonly used BNP and NT-proBNP immunoassays, a proficiency testing study, based on an external quality assessment scheme called CardioOrmocheck, was implemented in Italy in January 2005. In this article we report the results obtained in this multicenter study following activity from January 2005 to May 2008. 
Sample preparation
In total, 28 study samples with different BNP and NT-proBNP concentrations were prepared by the three central laboratories (Table 1) according to the ILAC G13 guidelines. These samples were then measured by all participating laboratories for a total of 2354 determinations; some of these same samples were analyzed repeatedly by all laboratories to evaluate within-laboratory variability. A summary of assay methods used to measure BNP and NT-proBNP are shown in Table 2 .
Study samples were prepared by pooling several plasma or serum specimens to obtain a sample pool with final volume of about 100 mL and immediately frozen at -208C. Different sample types were used, including EDTA plasma, Li-heparin plasma, or serum. All samples were tested to ensure absence of HBsAg, anti-HCV, and anti-HIV. Pools were prepared using residual serum or plasma from samples collected from apparently healthy subjects, also divided according to gender, and patients with cardiac diseases, with or without symptomatic heart failure. Demographic information about the 28 study samples are shown in Table 1 . Blood samples collected from ;30 to 50 healthy subjects or patients comprised each study sample. All study participants gave informed consensus for use of their residual blood samples. Study samples were lyophilized and then sent by mail to all participating laboratories. Lyophilization was performed by polymed (Sambuca, Firenze, Italy) within 2 weeks after preparation of the sample pools. Stored sample pools, were thawed, aliquoted into ;150 vials of 0.5 mL each, and then lyophilized. Typical temperature parameters for the lyophilization process were: -458C for freezing, -208C for the primary phase, q258C for secondary phase, and -608C for condensation. The time for each of the lyophilization steps were ;2 h for freezing, 24-36 h for primary phase evaporation, and ;18-24 h for secondary phase evaporation. The lyophilized materials were reconstituted with 0.5 mL of distilled water prior to analysis. BNP and NT-proBNP concentrations in all study samples were measured prior to, and following lyophilization, by the central laboratory (CNR Institute of Clinical Physiology in Pisa) in order to evaluate the recovery of BNP and NT-proBNP following the lyophilization Before, assay performed on the original plasma sample prior to lyophilization; After, assay performed on the reconstituted plasma following lyophilization; %, percent recovery. ACCESS, Access Beckman; TRIAGE, Triage Biosite; ADVIA, ADVIA Centaur Siemens; AxSYM, AxSym Abbott.
procedure, as well as the stability of BNP and NT-proBNP in the samples.
Statistical analysis
Statistical analysis of collected data was performed by the Department of Laboratory Medicine, CNR Institute of Clinical Physiology. Cumulative reports were prepared and sent by mail to each participant laboratory on a periodic basis. Participant laboratories could also access their individual data and cumulative reports online at http://www.ifc.cnr.it/eqas/. Total variability was estimated by averaging the CVs calculated from the results obtained on each study sample. This variability included both systematic between-method differences and differences between each of the laboratories. The imprecision of the different methods used by participant laboratories was estimated by averaging the CVs of results for the same study sample. Thus, the reported average CVs used for calculation of imprecision profiles was an estimate of the within-method and between-laboratories imprecision that was obtained.
Results

Study samples
BNP and NT-proBNP concentrations in all plasma pools were measured in the Laboratory of the CNR Institute of Clinical Physiology before and after lyophilization. Recovery (mean"SEM) following lyophilization was significantly higher (ps0.0006 by paired t-test) for NT-proBNP (87.8%"4.4%) measured using the ECLIA method on the Elecsys platform, than for BNP (66.8%"4.3%) measured using the Beckman ACCESS. Each study sample was measured at least four times using the ECLIA method for NT-proBNP and the ACCESS for BNP. We compared the recovery of BNP for different sample types. Recovery (mean"SD) was not significantly different between EDTA plasma (68.1%"24.7%), heparin plasma (52.2%"13.9%) or serum (64.5%).
Recovery following the lyophilization procedure was also assessed in five EDTA plasma samples with different concentrations of BNP and NT-proBNP and measured by the common methods for these analytes (see Table 3 ). Peptide concentrations were measured in duplicate using the original EDTA plasma samples and the lyophilized samples following reconstitution. BNP measured with the ADVIA Centaur showed the lowest recovery in lyophilized samples (mean recovery 52%, Table 3A ), while NT-proBNP measured using ECLIA on the Elecsys platform the highest recovery (mean recovery 91%, Table 3B ). The other BNP and NT-proBNP methods showed similar recoveries, ranging on average from 62% to 67%. Only the recovery of the ECLIA method was found to be significantly increased compared to the other BNP and NT-proBNP methods assays by means of one way factorial ANO-VA (p-0.001). The recovery of the ADVIA method was not significantly different when compared to other Before, assay performed on the original plasma sample prior to lyophilization; After, assay performed on the reconstituted plasma following lyophilization; %, percent recovery. ECLIA, ECLIA method with Elecsys platform; Dimension, Dimension Siemens. BNP methods, as assessed by one way factorial ANOVA, ps0.1027.
Assay methods
As shown in Table 2 , BNP assay methods were more commonly used compared with those for NT-proBNP (53% vs. 43%). The ECLIA system for NT-proBNP using the Elecsys and Modular platforms was the most commonly used method, with a utilization ratio of 41% (87% of utilization ratio among NT-proBNP methods only).
Variability estimation
The mean total variability (i.e., including variability among all methods and laboratories) for BNP (50.6 %CV) was significantly higher than that for NT-pro-BNP (8.4 %CV). Furthermore, the mean variability due to differences between-methods (46.4 %CV) included the predominant component of total variability observed for BNP comprising, on average, 84% of total variability. The within-method variability showed an average %CV of 20.2. On the contrary, withinmethod variability for NT-proBNP (7.3 %CV) represented the greater part of total variability, an average of 75%, while the between-method variability was smaller showing a %CV of 4.1. The imprecision profiles for the most common BNP assays in the survey are shown in Figure 1A . Large variability in imprecision among these methods was found. Imprecision profiles for the most common NTproBNP methods are given in Figure 1B . The ECLIA method on the Elecsys and Modular platforms showed better performance than the Dimension method, with a CV of -10% for the majority of the working range of the assay.
The BNP methods showed good correlation with correlation coefficient values ranging from Rs0.907 (correlation between ACCESS Beckman and ADVIA Siemens) to 0.986 (correlation between ACCESS Beckman and TRIAGE Biosite). However, a significant difference was found between mean BNP values measured with the Siemens ADVIA Centaur method and those measured using the other three methods as detected using the Scheffé test after ANOVA using log-transformed data (see Figure 2A) . In particular, the ADVIA method showed marked lower values compared with the AxSYM. An average difference of -20.8%, calculated as ADVIA-AxSYM/mean value % (p-0.0001 by Wilcoxon signed rank test), while the ACCESS showed an average difference of -24.9%, calculated as ADVIA-ACCCES/mean value % (p-0.0001). In addition, the AxSYM method gave BNP values significantly lower than those measured with the ACCESS method; on average a difference of -8.4% calculated as AxSYM-ACCCES/mean value % (p-0.0005). Finally, a significant difference was found between the mean value measured with the two ECLIA and Dimension methods ( Figure 2B ), although the difference was smaller than that seen for BNP methods.
Evaluation of matrix effects
In order to evaluate possible matrix effects on BNP and NT-proBNP immunoassays, some study samples with different matrix materials were prepared and assayed by all participant laboratories. These included one serum sample and three heparinized plasma samples ( Table 1) . The effect of sample matrix on the total variability of BNP or NT-proBNP assays was assessed by means of a stepwise multiple regression analysis. This analysis included total variability as the dependent variable and the concentration of BNP or NT-proBNP (log-transformation of original data) and matrix material (expressed as a dummy variable with 1 for EDTA and 2 for serum or heparin plasma) as independent variables. The matrix material variable showed no significant independent effect on the linear negative regression between total variability and BNP (Rs0.445, ps0.0137) or NT-proBNP (Rs0.378, ps0.0395).
Discussion
Theoretical limitations and aims of the study
There are some theoretical limitations concerning a proficiency testing study for BNP and NT-proBNP immunoassay methods. The specifications for measurement of BNP recommend the use of EDTA plasma samples, while serum is the preferred sample for NTproBNP (10) . Furthermore, the use of EDTA plasma samples is not recommended by the manufacturers for some NT-proBNP immunoassays, such as the method used on the Dimension platform (13) . Following the manufacturer's recommendations and quality specifications, at least two different human blood samples should be used in a proficiency testing study for BNP and NT-proBNP: EDTA plasma for BNP methods, and serum for NT-proBNP. Alternatively, an artificial material could be prepared, which is commutable for all BNP and NT-proBNP immunoassay methods. Unfortunately, to our knowledge, this type of material is not presently available.
In order to reduce the in vitro degradation, especially for BNP, and to make the distribution and measurement of blood samples easier, we decided to use lyophilized plasma and serum samples only. It is important to note that both plasma or serum samples are actually used for the measurement of BNP and its related peptides. Thus, our protocol is in accordance with actual laboratory practice.
The primary aim of the CardioOrmocheck study is to answer the theoretical limitations of a proficiency study of methods for BNP and NT-proBNP that use human plasma or serum samples. Although some differences in the recovery of lyophilized samples were observed between immunoassay methods (Table 3) , the results obtained in the present study are in agreement with previously reported data (2, 14) . This supports the suitability of this material for between-method comparisons. The results of the CardioOrmocheck study suggest that it is possible to perform a reliable proficiency testing study for BNP and NT-proBNP immunoassay methods using lyophilized serum or plasma samples pools collected from well-characterized groups of healthy subjects or cardiac patients with or without heart failure.
Another important aim of the CardioOrmocheck study was to mimic the actual laboratory and clinical situations associated with measurement of BNP and NT-proBNP. Although the results of the CardioOrmocheck study are relevant to conditions seen in Italian laboratories, some of the results of this study may have a more general relevance, as discussed above.
Results and discussion
Since BNP and NT-proBNP differ in biochemical structure, molecular weight, biological activity and degradation pathways (1, 2, 12) , it is not surprising that BNP and NT-proBNP assay methods may also have different analytical characteristics and quality specifications. The biologically active peptide, BNP, shows a shorter half-life and a more rapid degradation rate both in vivo and in vitro than the inactive peptide, NTproBNP (1, 2). As a result, the biological variation of NT-proBNP is smaller than that of BNP (15) . Furthermore, BNP degradation in vitro is minimized by the use of EDTA and/or other inhibitors of plasma proteases, such as the aprotinin (2, (9) (10) (11) (12) . Indeed, quality specifications for BNP assays recommend the use of EDTA plasma samples (10, 11) . On the contrary, previous data (16) (17) (18) , as well as the results of the present study, suggest that the NT-proBNP assay can be performed in serum as well as EDTA or heparinized plasma. However, possible matrix effects due to the use of anticoagulation with EDTA or heparin should be tested (12, (16) (17) (18) . Data from this study demonstrate that there are wide differences in analytical characteristics among immunoassay methods. In particular, the imprecision around the cut-off values (corresponding to 50-100 ng/L for BNP and 100-150 ng/L for NT-proBNP, respectively) (4, 12) showed marked differences among methods (Figure 2 ). Only the two ECLIA methods for NT-proBNP showed imprecision profiles F10 %CV around the cut-off values (i.e., about 100-150 ng/L), while the Dimension method for NT-proBNP and Access and ADVIA Siemens for BNP (cut-off value about 50 ng/L) showed imprecision below 20%. The other immunoassays demonstrated even worse imprecision values.
The results of the CardioOrmocheck study confirm that the most common BNP immunoassays are affected by large systematic differences (on average, 2.7-fold between the Access and ADVIA Centaur methods, Figure 2A ). Agreement between NT-proBNP methods was better (on average 1.2-fold difference between the Dimension and ECLIA on Elecsys platform methods, Figure 2B ). These results were largely expected because all the commercial NT-proBNP methods tested in the study, the two ECLIA methods and the Dimension method, use antibodies and standard materials from the same source (Roche Diagnostics), while BNP methods use different antibodies and standard materials (2, (9) (10) (11) (12) . In particular, the automated BNP immunoassays on the AxSYM and ACCESS, and the POCT method on the TRIAGE Biosite shared similar BNP values (Figure 2A ). Only the fully-automated ADVIA Centaur method and the immunometric assay (IRMA) by Shionogi (data not shown), which use the same antibodies, showed significantly lower results compared with the other methods. The present study is in close agreement with previous studies comparing the analytical performance and diagnostic accuracy of some BNP assays (14) . The results of CardioOrmocheck study confirm that is not reasonable to suggest similar cutoff or decision values for all BNP assays (2, 12, 14) .
Conclusions
The present study suggests that there are several theoretical and practical limitations to performing a proficiency study for BNP and NT-proBNP immunoassay methods due to non-homogeneity and possible noncommutability of human plasma and serum samples. In addition, there are differences in recovery of analyte following lyophilization. Moreover, our data confirm that there are marked differences in the analytical characteristics and measured values among the most commonly used commercial methods for BNP and NT-proBNP. Therefore, clinicians should carefully evaluate results obtained by different laboratories, especially when different methods are used. Furthermore, our findings confirm that standardization is necessary for immunoassay methods, especially for those that measure BNP.
